SYNTHOS RESEARCH

Chubb CB

Financial Services · Insurance - Property & Casualty · Synthos Deep Dive · 2026-07-03

$361.17
Hold
Risk 3Growth 6Exponential 3Fair value $355 $270–$430

At a glance

VerdictHold — systematic Synthos tier
Price (2026-07-02)$361.17 · market cap ~$140B
Synthos scores (0–10)Downside Risk 3 · Growth Quality 6 · Exponential Potential 3
Synthos fair value (base case)~$355−2% · full range $270 (bear) – $430 (bull)
Street consensus$346.75 (high $373 / low $309; 23 Buy · 18 Hold · 2 Sell) — note: below the current price
Valuation~13× FY26E / ~12× FY27E EPS · 12.7× trailing · P/B 1.9× · EV/EBITDA 12.5×
Exponential Potential3/10 · Low — a mature ~$140B global insurer; ~3% forward revenue growth, ~7% EPS growth, decelerating into a softening P&C market
TechnicalsUptrend but stretched — $361, at the 52-wk high, above 50/200-DMA, RSI 77.5 (overbought), +24.7% 12-mo (SPY +20.6%)
ConvictionNone — 0 expert voices, 0 traceable claims in the Synthos KB; this is a quant/fundamentals call
Position sizingIf owned, a low-beta defensive ballast holding, ~2–4%; not a high-conviction buy here
Next catalyst2026-07-21 Q2'26 earnings (Street EPS $6.72, revenue ~$15.1B)
Single biggest riskA soft/softening P&C pricing cycle compresses underwriting margins just as a major catastrophe year hits

One-line thesis. Chubb is one of the best-underwritten, most disciplined global P&C insurers on earth — fortress balance sheet, ~20% core operating return on tangible equity, low beta — but it's a mature, cyclical compounder trading above its own Street price target at a 52-week high with an overbought tape, so the honest call is Watch and wait for a better entry, not chase.

◆ Synthos call — Hold CB is a solid business largely reflected at ~$355 — fine to keep, no reason to chase; it gets interesting again below ~$302.
Downside Risk (lower = safer)
3/10 · Low
Fortress balance sheet, beta 0.42, net-debt/EBITDA 1.2×, 13× earnings — but it's a CAT-exposed P&C cyclical priced above its own Street target.
Growth Quality
6/10 · High
~7% forward EPS CAGR, record ROTE ~20%, disciplined underwriting — solid, not a fast grower; top line only ~3%/yr forward.
Exponential Potential
3/10 · Low
Mature global insurer decelerating into a soft P&C market; $140B cap and single-digit growth cap any multibagger.
⚖ Reverse-DCF cross-check Market-implied growth ≈ 16%/yr To justify today’s $361, earnings would have to compound roughly 16% a year for 10 years (9% discount rate). Analysts forecast ~15%/yr, so the market is pricing in about what the Street expects.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

Chubb sells insurance — for businesses (property, liability, workers' comp, cyber, marine) and for well-off families (homes, cars, valuables), all over the world, plus a growing life-insurance arm in Asia and Latin America. It makes money two ways: the profit on the policies it writes (it's unusually good at this — it collects more in premiums than it pays out in claims) and the investment income on the huge pile of premium cash it holds before claims come due.

Is the stock cheap or expensive? It's roughly fairly priced — maybe a touch full. You're paying about 13 times earnings, which is reasonable for a high-quality insurer, but the stock has run up to a record high and even Wall Street's average price target is slightly below today's price. That's why our verdict is Watch: great company, not a great entry point right now.

Here's what our three scores mean in everyday terms:

The one big worry: insurance pricing is softening — Chubb's own CEO said parts of the property market are getting cheaper "at a rapid pace." When prices soften and a big catastrophe year hits, insurer profits get squeezed.


Price & moving averages 12 months · 50 & 200-day averages · 52-week range

258286314341369Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2652w hi $361Price 36150-DMA 327200-DMA 31152w lo $266

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

254283312340369Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26Price 36120-day avg 332

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

705030Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26RSI 74.4

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 74.

MACD 12 / 26 / 9 · trend & momentum

0Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26MACD 7.0signal 3.9

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago

8899110121132Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26CB 129S&P 500 120XLF (sector) 106

Solid = CB · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

018365573$36BFY21EPS $12$41BFY22EPS $15$54BFY23EPS $24$52BFY24EPS $22$55BFY25EPS $24$59BFY26EEPS $27$62BFY27EEPS $29$65BFY28EEPS $32

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$361.17
Market cap$140B
P/E trailing16×
P/E FY26E / FY27E13× / 12×
EV / Sales2.5×
EV / EBITDA12.5×
Gross margin35.2%
Net margin18.5%
Dividend yield1.09%
Beta0.421
52-wk range$266 – $361
RSI(14)78
50 / 200-DMA$327 / $311
12-mo return+25% (SPY +21%)
Street target$347 ($309–$373)
Analyst grades22 Buy · 18 Hold · 2 Sell
FMP ratingA-
Next earnings2026-08-05

What the experts actually said 0 traceable claims on CB · showing the highest-conviction voices

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

Chubb Limited (NYSE: CB) is a Zurich-headquartered global insurer and reinsurer — the world's largest publicly traded property & casualty (P&C) insurer by market cap. It was formed from the 2016 combination of ACE Limited and the old Chubb Corporation (ACE took the Chubb name). Led by long-tenured Chairman & CEO Evan G. Greenberg, it writes commercial and personal P&C, agriculture, global reinsurance (Chubb Tempest Re), and a fast-growing international Life Insurance book. Fiscal year ends December 31. ~43,000 employees.

The business has four engines:

1. North America Commercial P&C — large corporate, middle-market and small commercial (property, casualty, financial lines, cyber, workers' comp, surety).

2. North America Personal P&C — high-net-worth homeowners, auto, valuables, excess liability (its signature affluent-client niche), plus crop/agriculture.

3. Overseas General Insurance — commercial and consumer lines across Europe, Asia and Latin America (the fastest-growing region).

4. Global Reinsurance and Life Insurance (protection and savings, concentrated in Asia/LatAm).

Revenue mix (FY2025, from filings):

The strategic story is (a) underwriting discipline — walking away from underpriced business (Q1'26: they non-renewed a large chunk of shared/layered property in a soft market), (b) record investment income on a higher-rate portfolio, and (c) international consumer + Life as the durable growth leg.

2. The expert thesis

There is no expert coverage of Chubb in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0. No podcast host, fund manager, or analyst in our tracked panel has an on-record, distilled claim on CB.

That matters for how you read this note: every judgment below is fundamentals- and quant-driven — built from the FMP financials, analyst consensus estimates (labeled as estimates), management's own SEC-filed earnings release, and Synthos's scoring framework. We are not borrowing anyone's conviction, and we will not manufacture it. When a name has zero KB breadth, the verdict leans deliberately conservative and the position sizing small, because we have no independent expert signal to corroborate the quant read. Here, the quant read alone lands on Watch.

(If/when a tracked voice initiates coverage, this section and the conviction rating will update in a later version.)

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score0–10The read
Downside Risk (lower = safer)3 · Low-ModerateBeta 0.42, net-debt/EBITDA 1.2×, 12.7× trailing earnings, A- letter rating, zero drawdown from peak — genuinely defensive. The offsets: it's a catastrophe-exposed cyclical in a softening pricing market, trading above its own Street target at a 52-wk high with RSI 77.
Growth Quality6 · GoodRecord core operating ROTE ~20.6%, ROE ~15.6% TTM, disciplined ~84% combined ratio, ~7% forward EPS CAGR and double-digit book-value growth — high-quality, but structurally single-digit-growth and margin-sensitive to the cycle.
Exponential Potential3 · LowA mature ~$140B insurer; revenue growth decelerating (FY25 +6.5% → ~3%/yr forward), no acceleration, and law-of-large-numbers caps upside. Compounds; does not multibag.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.

CaseKey assumptionsFair value
BullP&C pricing re-firms, a benign catastrophe year, investment income keeps rising; FY27E EPS beats to ~$31 and the market pays a premium ~14× for the quality.~$430 (+19%)
Base (our anchor)Estimates roughly hit — FY26E EPS $27.1, FY27E $29.3; a durable low-double-digit compounder holds its ~12–12.5× forward multiple and grows book value.~$355 (−2%)
BearSoft market deepens, a heavy CAT year (hurricane/wildfire) lifts the combined ratio, investment marks hurt book value; FY27E EPS misses toward ~$26 and the multiple de-rates to ~10.5×.~$270 (−25%)

Synthos fair value = the base case, ~$355 (−2%), with the full $270–$430 span as the honest range. Our base sits essentially on top of the Street's $346.75 consensus (which is itself below the current $361 price) — i.e. by our math and the Street's, the stock is priced for its quality with little margin of safety left after a strong run. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). Chubb is a high-quality compounder with essentially no exponential profile:

Exponential Potential: Low (3/10). Own Chubb (if at all) for defensive, low-beta, book-value-plus-dividend compounding, never for a fast multibagger. This honest framing is why it does not belong in a growth/degen sleeve.

5. Financials (real numbers — FMP annual/quarterly + management release)

6. Valuation — priced in or room?

Chubb is fair-to-full, not cheap and not egregious. Trailing 12.7× EPS, forward ~13.3× FY26E / ~12.3× FY27E / ~11.3× FY28E, P/B 1.9×, EV/EBITDA 12.5×, dividend yield ~1.1% (payout only ~13% — well-covered, lots of buyback capacity). For a P&C insurer earning ~20% ROTE, ~12–13× forward earnings and ~1.9× book is a reasonable-to-slightly-rich multiple — insurers typically trade 1.3–2.0× book depending on ROE, and Chubb sits near the top of that band, appropriately, given its quality.

The tell that upside is limited: the stock ($361) trades above the Street's $346.75 consensus target (high $373 / low $309). When price exceeds the median analyst target after a 25% twelve-month run, the market has already paid for the quality. A reverse read: at ~1.9× a book value growing low-double-digits, you're underwriting mid-single-digit annual returns from here plus the dividend — a solid defensive return, not a mispricing. Street targets (context): consensus $346.75, high $373, low $309 — our ~$355 base FV sits right in that cluster. Not a value buy; a quality-at-fair-value hold.

7. Technicals (from the tech block)

8. Moat & competitive position

Chubb's moat is underwriting culture, scale, and a fortress balance sheet rather than a patent or network effect: (1) decades of disciplined underwriting produce a structurally lower combined ratio than most peers (84% in Q1'26); (2) global scale and diversification across lines/geographies smooth catastrophe volatility; (3) a high-net-worth personal-lines franchise (affluent homeowners/auto/valuables) that is genuinely hard to replicate and commands pricing power; (4) a large, high-quality investment float that throws off record investment income in a higher-rate world; (5) A- financial strength that wins large, complex risks smaller insurers can't hold. The binding constraint is cyclicality — even the best underwriter can't fully escape a soft pricing market or a heavy CAT year.

Peer set (FMP-supplied, market cap). Note FMP's peer list is a generic "large financials" basket — the relevant P&C/insurance comps are the last three: Progressive $136B (personal auto, the growth comp), Travelers $73B (US commercial/personal P&C), and Marsh & McLennan $90B (insurance broker, adjacent). The rest — Bank of America $417B, BBVA $143B, Bank of Montreal $122B, UBS $167B, ICICI $106B, KKR $84B, Interactive Brokers $40B — are banks/brokers/asset managers, not underwriting comps, and should be read as sector context only. Against TRV and PGR, Chubb is the largest, most globally diversified, and most consistently disciplined underwriter, which supports its premium-to-book valuation.

9. Management, capital allocation & guidance

10. Catalysts & what to watch

Thesis tripwires (what would change the call): combined ratio sustainably above ~90%; two consecutive quarters of P&C premium declines from the soft market; book-value-per-share growth stalling below high-single-digits; or a valuation re-rating well above ~1.9× book (which would tip Watch toward Avoid on price).

11. Key risks

12. Verdict, position sizing & monitoring

Watch. Chubb is a genuinely excellent company — arguably the best-underwritten large global P&C insurer, with a fortress balance sheet (net-debt/EBITDA 1.2×, A-), low beta (0.42), record ~20% core operating ROTE, disciplined capital return, and a candid, high-quality management team. The problem is price and timing, not quality: at $361 the stock trades above its own Street consensus target ($346.75), at a 52-week high, with an overbought RSI of 77, into a pricing cycle management itself calls "soft or softening." Our base-case fair value (~$355) sits right on the Street and essentially on top of today's price — thin upside, real cyclical downside. With zero expert coverage in the KB, we have no independent conviction to justify chasing.

What would move this to Buy: a 10–15% pullback (toward ~$310–$327) restoring a margin of safety, evidence the soft market is stabilizing, or a clean benign-CAT year re-accelerating book-value growth — any of which would make the quality worth paying up for.


Provenance & disclosures